Top Five Healthcare M&A Deals of 2024

12. Siemens Healthineers acquired Novartis’ Advanced Accelerator Applications (AAA), significantly expanding its molecular imaging capabilities. This transaction added 13 production sites across Europe to Siemens’ PETNET Solutions network, strengthening its original equipment manufacturer (OEM) capacity for producing and delivering PET radiopharmaceuticals. The newly integrated workforce of approximately 420 employees will operate as Advanced Accelerator Applications under Siemens Healthineers. According to Siemens, the PET diagnostics market covered by this acquisition generates annual revenues of €500 million—driven by tracer innovations in oncology, neurology, and cardiology—and is projected to triple by 2033. PETNET Solutions is the global leader in PET radiopharmaceutical production and distribution, supplying nearly 1.6 million doses annually to over 2,800 imaging centers worldwide. 4. Duke Street Acquires AGITO Medical from Philips In July, European private equity firm Duke Street acquired Denmark-based AGITO Medical—a mobile imaging equipment leasing and pre-owned imaging systems supplier—from Philips. Founded in 2004, AGITO provides flexible, customized mobile imaging leasing solutions—including CT, MR, and ECG suites—to hospitals and clinics, with optional staffing services. It also supplies refurbished imaging equipment and spare parts. James Almond, Duke Street’s Executive Partner, described the investment as a ‘classic’ private equity deal: spinning off an excellent healthcare product and team from a global corporate, then creating value for all stakeholders through a dedicated investment plan. The European medical imaging leasing market is currently valued at approximately €500 million and is expected to grow 6–7% annually over the coming years. 5. Avante Health Solutions Files for Chapter 11 Bankruptcy and Agrees to Sale In October, Avante Health Solutions and its affiliated entities filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware on October 8, aiming to advance their sale process to private equity firm Staple Street Capital. The company reported assets valued between $50 million and $100 million, and liabilities between $100 million and $500 million—including its top unsecured creditor, Philips Medical Systems. Jim Leitl, Avante’s CEO and President, stated: “Facing persistent litigation, our team has worked diligently to strengthen our financial foundation. Over the past several years, Avante has incurred losses totaling approximately $20 million.”

Embodied AI Is Still Losing Money, But Sellers of ‘Hands’ Are Already Profiting

Wang Yuquan, founder of Hywin Capital, points out that humanoid robots do contain bubbles—but not everything about them is speculative. He believes the bubble is especially large if the focus lies solely on legs; by contrast, developing robotic arms and dexterous manipulation capabilities holds greater intrinsic value—because operational capability is what will truly matter in the future. ‘Hands’ Are the Most Expensive Component Before diving into dexterous hands, consider the numbers. Morgan Stanley estimates that dexterous hands account for roughly 17.3% of Tesla’s Optimus robot’s bill of materials (BOM), costing approximately $8,650–$10,380. Similarly, China Post Securities’ teardown report on Unitree’s G1 humanoid robot notes that dexterous hands constitute around 18% of its total hardware cost. Given their high technical difficulty and manufacturing expense—and excluding software and algorithmic value—dexterous hands rank among the most valuable hardware components in a humanoid robot. Breaking it down further reveals why dexterous hands command such high prices. A senior executive at a dexterous-hand startup provided more intuitive figures: over half of a single dexterous hand’s cost comes from its actuation module—including motors, gearboxes, and joint modules; sensors and structural components follow. Hollow-cup motors alone account for ~41% of the hand’s total cost; frameless torque motors plus drivers for linear joints represent 15–25%; and the entire motor system collectively accounts for the remaining 20–30%. A robotics engineer explained that industry-standard direct-drive dexterous hands typically cost over ¥1,000 (approx. $140) per degree of freedom (DoF); with 22 DoFs per hand, procurement costs alone reach ¥20,000–¥30,000 ($2,800–$4,200). Adding other components and R&D expenses, selling prices routinely range from tens of thousands to over ¥100,000 ($14,000) per unit. ‘This technology pathway inherently dictates pricing—no one operates at a loss, and dexterous hands are no exception,’ the engineer concluded. Behind the ‘high price’ lies ‘high profit’—a trend further validated in the latest semi-annual financial reports. Weihong Co., Ltd.’s interim report shows its dexterous-hand joint motors/modules shipped over 50,000 units, with products already embedded in leading domestic and international robot supply chains. Its Q2 revenue reached ¥169 million ($23.5 million), up 19.06% year-on-year; net profit attributable to shareholders was ¥23.95 million ($3.3 million), up 48.48%. Leadshine Intelligent’s robotics business has likewise entered a monetization phase: from January to August 2026, its dexterous-hand sales exceeded 4,000 units—doubling year-on-year. In H1, the company achieved ¥1.247 billion ($173 million) in revenue (up 39.92%) and ¥194 million ($27 million) in net profit (up 62.79%). Although Fulaixin New Materials hasn’t disclosed specific revenue from its dexterous-hand business, order volumes clearly surged. In December 2025, Fulaixin delivered 1,000 sets of tactile sensors to Lingxin Qiao Shou; in February this year, both parties signed a procurement agreement for 100,000 sets; and in August, Zhongke Guiji proposed a new order for 200,000 sets. Such continuous demand signals strong performance outlooks for upcoming quarters. Guojin Securities’ research report further states that the robotics ecosystem is entering a virtuous cycle—from upstream capital expenditure increases and hardware cost reductions, to midstream technological advancement and downstream practicality improvements. This dynamic is expected to sustain new market catalysts, with dexterous hands potentially commanding over 30% of total robot hardware value.

Avient Corporation: Strong Q2 Results Meet Abrupt CEO Change

Oct 12, 2026

Avient Corporation reported robust Q2 results exceeding revenue expectations and raised its 2026 guidance despite an abrupt CEO departure causing stock volatility. Analysts maintain a Hold rating amid market uncertainty while reaffirming Q3 guidance.

Seeking Alpha

2026-05-05

Avient Corp CEO Ashish K. Khandpur Identified

2026-10-09

Avient Corp Elects Michael J. Frank as President and CEO

2026-10-09

Avient (AVNT) Names Mike Frank as CEO, Signals Strategic Shift

2026-10-09

Avient Corporation Appoints Michael J. Frank as CEO, Succeeding Ashish Khandpur

2026-10-09

Avient names former Monsanto exec to replace departing CEO